Register By 5th August
And Save Up To €600

16th-18th November 2016
Munich, Germany

2nd Annual ICI Europe Immune Checkpoint Inhibitors

- **Identify Clinically Effective Combinations**
- **Assess Novel Target Pathways**
- **Validate Patient Selection Biomarkers**

23 Expert Speakers Including:

Roger Dansey
SVP, Global Clinical Development Oncology
MSD

Sabine Maier
Group Director, Medical Lead, Global Clinical Research Oncology
Bristol-Myers Squibb

Jun Wang
Senior Medical Director
Genentech

Jessie English
VP, Head of Discovery Research
EMD Serono

Markus Mohrs
Director, Immuno-Oncology
Regeneron

Catherine Sabatos-Peyton
Senior Investigator II
Novartis

Sukhvinder Sidhu
Head of Pharmacology, Oncology Drug Discovery & Preclinical Development
Sanofi

Nicolai Wagtmann
EVP & CSO
Innate Pharma

Tom Lillie
VP, Head of European Clinical Development
MSD

Partners:

ABZENA
Enabling better biopharmaceuticals

CAPRION

> "This conference was of outstanding value. First class presentations, great opportunity for networking and perfect logistics!"
>
> **AstraZeneca, Attendee 2015**

www.immunecheckpoint-europe.com

Tel: +44 203 141 8700 | **Email:** info@hansonwade.com

Immune Checkpoint Inhibitors @ICI_checkpoint

Researched & Developed By:
hansonwade
love what you do

Welcome to the 2nd Annual Immune Checkpoint Inhibitors Europe

Seize The Potential Of Immune Checkpoint Inhibitors

The unprecedented clinical and commercial success of immune checkpoint inhibitors over the last 12 months has seen an explosion of interest in the field. With over 1000 clinical trials involving ICIs currently taking place, **are you doing enough to keep pace with the rapidly evolving immuno-oncology space?**

Focused exclusively on how to deliver maximum clinical benefit through immune checkpoint monotherapy and combinations, **ICI Europe** will provide you with actionable insights to enable you to realise the potential of the next generation of immune checkpoint inhibitors more rapidly.

Join experts from MSD, BMS, Genentech and Novartis to benchmark your progress and discuss key topics such as **validating clinically relevant biomarkers, defining rational combination studies** and **uncovering the next generation of immune checkpoint pathways.**

Top 10 Reasons To Attend ICI Europe 2016

1. **Enhance the synergy of immuno-oncology combinations** by optimising the scheduling, dosing and timing of interventions
2. **Target resources more effectively** by investigating clinically relevant biomarkers to identify responding populations
3. **Broaden the efficacy of immunotherapy** by targeting diverse cell types such as NK cells and myeloid-derived suppressor cells as well as T cell immune checkpoints
4. **Understand the rationale behind combination strategies** by interrogating the underlying biology
5. **Balance translatability with cost-effectiveness** by investigating the relative advantages of syngeneic, transgenic and humanized *in vivo* mouse models
6. **Translate results into the clinic more successfully** by learning about robust preclinical approaches to model checkpoint inhibitor combinations
7. **Improve immune responses** by increasing your understanding of the suppressive tumour microenvironment
8. Seize the opportunities presented by the next generation of immune checkpoint inhibitors by learning how they can **overcome mechanisms of resistance and target larger patient populations**
9. **Discover the true clinical potential** of the next generation of immune checkpoint pathways, including IDO1, SIRP-alpha, LAG-3 and TIM-3
10. **Analyse new and innovative checkpoint targeting approaches** including bispecific constructs and localised administration

Tel: +44 203 141 8700 **Email:** info@hansonwade.com
www.immunecheckpoint-europe.com Immune Checkpoint Inhibitors @ICI_checkpoint

Speakers

Gary Bembridge
Senior Director, Scientific Affair
Abzena

Speaker to be confirmed
Caprion

Roger Dansey
SVP, Global Clinical Development Oncology
MSD

Tanja de Gruij
Head, Immunotherapy Lab
Cancer Center Amsterdam

Jessie English
VP, Head of Discovery Research
EMD Serono

Udo Gaipl
Head of Radiation Immunobiology University Hospital
Erlangen

Arnold Gelb
Senior Director, Clinical Biomarkers & Companion Diagnostics
EMD Serono

Markus Hecht
Radiation Oncologist
University Hospital Erlangen

Marlon Hinner
Director, Immuno-Oncology
Pieris

Zahra Jawad
Team Leader, Antibody Phage Display
Agenus

Sandra Li
Scientist, Pharmacodynamics & Translational Medicine
Ablynx

Tom Lillie
VP, Head of European Clinical Development
MSD

Rosalie Luiten
Principal Investigator, Immunodermatology Research
University of Amsterdam

Sabine Maier
Group Director, Medical Lead, Global Clinical Research Oncology
Bristol-Myers Squibb

Markus Mohrs
Director, Immuno-Oncology
Regeneron

Catherine Sabatos-Peyton
Senior Investigator II
Novartis

Bastian Schilling
Researcher, Dermatology Study Centre Coordinator
University Hospital Essen

Sukhvinder Sidhu
Head of Pharmacology, Oncology Drug Discovery & Preclinical Development
Sanofi

Bernard Vanhove
CEO
Effimune

Niina Veitonmäki
Head, *In Vivo* Oncology
Alligator Bioscience

Nicolai Wagtmann
EVP & CSO
Innate Pharma

Jun Wang
Senior Medical Director
Genentech

Alan Wise
CEO
IOmet Pharma

"Excellent meeting. Great opportunity for discussions between academia, small start ups, large pharma and regulatory authorities." **MSD**

"Perfect organization. Program well planned with sufficient time for networking." **BMS**

Conference Agenda, Day One – Wednesday 16th November

07:50 **Registration & Networking**

08:20 **Chair's Opening Remarks**

Tom Lillie, VP, Head of European Clinical Development, **MSD**

08:30 **Keynote: Cutting Through The Noise And Speculation: Insights Into The Transitional Dynamics At Play In The ICI Space To Make Informed Decisions About Future Strategy**

- Examine the impact of the recent Checkmate 012 study on the immune checkpoint inhibitors space
- Evaluate factors influencing effective combination strategies
- Discuss how the priorities of the ICI community will evolve over the next 5 years

Sabine Maier, Group Director, Medical Lead, Global Clinical Research Oncology, **Bristol Myers Squibb**

Maximise Responses Through Rational Combination Strategies

09:00 **Keynote: Enhancing Patient Outcomes With Pembrolizumab In Combination Strategies**

- Investigate diverse combination strategies with pembrolizumab
- Critical considerations for developing effective combination strategies – improving outcomes and maintaining tolerability
- Understand clinical combinations: Biologic rationale and expecting the unexpected

Roger Dansey, SVP, Global Clinical Development Oncology, **MSD**

09:30 **Enhance Anti-Tumour Immune Responses Through Bifunctional Checkpoint Targeting Immunotherapies**

- Discuss PD-L1 and TGF-alpha targeting bifunctional molecule M7824
- Investigate the ability of M7824 to overcome mechanisms of resistance and control tumour growth
- Insights into the rationale behind bifunctional immunotherapies in contrast to monospecific and combination approaches

Jessie English, VP, Head of Discovery Research, **EMD Serono**

10:00 **Speed Networking**

11:00 **Morning Refreshments**

11:30 **Further Details To Be Confirmed Soon**

CAPRION

11:45 **Rationales For The Combination Of Radiotherapy With Immune Checkpoint Inhibitors**

- Depict the immune modulatory effects of radiotherapy
- Discuss the immune biological basis for combining radiotherapy with immune checkpoint inhibitors
- Understand scheduling, dosing, timing, and time frame of responses to radioimmunotherapy

Udo Gaipl, Head of Radiation Immunobiology, **University Hospital Erlangen**

12:00 **Preclinical And Clinical Findings For The Combination Of Radiotherapy With Immune Checkpoint Inhibitors In Future Studies**

- Preclinical findings about radiation doses and fractionation in combination with PD-1/PD-L1 pathway blockade
- Preclinical findings about the timing of radiation and administration of PD-1/PD-L1 inhibitors
- Clinical results of the combination of radiotherapy with CTLA-4 blockade

Markus Hecht, Radiation Oncologist, **University Hospital Erlangen**

12:15 **Speaker Q&A Session**

12:25 **Mastermind: Discussing The Key Factors In Ensuring Synergy In ICI Combination Approaches**

- Discuss rational strategies to incorporate ICIs as integral components of combinatorial therapeutic strategies
- Investigate methods to address timing, scheduling and dosing challenges in combination trials
- Overcome combination-associated toxicities
- Perspectives on the future of successful combination strategies that will maximise the efficacy of ICIs

This session facilitates in-depth discussions between participants in an informal environment. After splitting into small groups, participants discuss the key considerations required to assess combination approaches and perspectives on the future of the immuno-oncology field

13:00 **Lunch & Networking**

Validate Clinically Predictive Biomarkers

14:30 **A Systematic Review Of Predictive Biomarkers For ICI Response**

- Learn about the systematic review methodology for clinical biomarker studies
- Current state of research on predictive biomarkers associated with ICI response and/or survival
- Identify promising and contradictory findings in biomarker research

Rosalie Luiten, Principal Investigator, Immunodermatology Research, **University of Amsterdam**

15:00 **Developing robust biomarkers to select patients for monotherapy and combination trials**

- PD-L1 – progress in predicting benefit
- Refining biomarker strategies in the era of combinations - Moving from single markers to a signature approach
- Insights into MSD's biomarker strategy – PD-L1/2, immune marker profiles, MSI and mutation burden

Tom Lillie, VP, Head of European Clinical Development, **MSD**

15:30 **Current Status Of PD-L1 As A Biomarker And Companion Diagnostics**

- Gain an overview and update on PD-1/PD-L1 with emphasis on PD-L1
- Examine the Blueprint Initiative (Phase 1 results and planning for Phase 2)
- Look beyond PD-L1 as a single, IHC-based biomarker

Arnold Gelb, Senior Director, Clinical Biomarkers and Companion Diagnostics, **EMD Serono**

16:00 **Afternoon Break & Refreshments**

Enhancing Preclinical Development To Improve Clinical Outcomes

16:30 **Advances in *In Vitro* PBMC Assays to Measure Functionality of ICIs Preclinically**

Gary Bembridge, Senior Director, Scientific Affairs, **Abzena**

17:00 **Of Mice And Men: Investigating Syngeneic, Transgenic And Humanised Immuno-Oncology Mouse Models**

- Overcome the challenges involved in developing humanised mouse models
- Investigate whether immuno-oncology models are made easier with transgenic mice
- Discover the effects of health and immunological status of mice on CTLA-4 and PD-1 response: Is the standardization of microflora the future?

Niina Veitonmäki, Head, *In Vivo* Oncology, **Alligator Bioscience**

17:30 **Enhancing The Preclinical Development Of Checkpoint Inhibitors And Combinations**

- Innovate preclinical approaches to model immune checkpoint inhibitor combinations
- Utilise Velocigene technology to develop robust humanised mouse models
- Learn about translational insights to support the development of REGN2810 and the next generation of immune checkpoint inhibitors

Markus Mohrs, Director, Immuno-Oncology, **Regeneron**

18:00 **Chair's Closing Remarks**

Tom Lillie, VP, Head of European Clinical Development, **MSD**

Conference Agenda, Day Two – Thursday 17th November

08:00 **Registration & Networking**

08:20 **Chair's Opening Remarks**

Tom Lillie, VP, Head of European Clinical Development, **MSD**

08:30 **The Atezolizumab Combination Approach: Structured Immuno-Oncology Combination Strategies To Maximise Efficacy**

- Pioneer a comprehensive multi-strategy, multi-indication combination strategy for atezolizumab
- Utilise biomarkers to tailor combination approaches
- Learn lessons from the clinical development of atezolizumab: Shaping future strategy from prior clinical success

Jun Wang, Senior Medical Director, **Genentech**

Pioneering Novel Checkpoint Pathways Beyond PD-1, PD-L1 and CTLA-4

09:00 **LAG-3 And TIM-3 Checkpoint Inhibitors: Into The Clinic And Back To The Bench**

- Discuss combination of PD-1 blockade with LAG-3 or TIM-3, and how additional checkpoint blockade may address more than one mechanism of inhibition in the tumour microenviroment (TME)
- Investigate the role of TIM-3 and its blockade in cancer beyond T cells, notably as an inhibitory/tolerogenic molecule on myeloid cells
- Discover how combined learnings from murine syngeneic models and profiling/*ex vivo* functional assays with tumour-infiltrating lymphocytes can inform understanding of immune cells in the TME

Catherine Sabatos-Peyton, Senior Investigator II, **Novartis**

09:30 **Broadening The Scope: Targeting Checkpoint Receptors On Natural Killer Cells To Mount Anti-Tumour Immune Responses**

- Dissect the rationale behind NK cell-targeted immune checkpoint modulation as a monotherapy and in combination
- Insights into combination strategies targeting NK cell and T cell immune checkpoints
- Examine the design of clinical trials to harness the innate and adaptive immune responses

Nicolai Wagtmann, EVP & CSO, **Innate Pharma**

10:00 **Morning Refreshments & Networking**

10:30 **Selective Targeting Of The SIRP-alpha Immune Checkpoint To Dampen Suppression By Myeloïd-Derived Suppressor Cells And Control Polarization Of Human Macrophages**

- Hear how SIRP-alpha, first identified in transplant tolerance setting, is controlling the differentiation and function of myeloid cells
- Discuss how SIRP-alpha antagonists can be used to enhance anti-tumour T cell function
- Define what therapeutic combination best synergizes with SIRP-alpha antagonists in hepatocarcinoma, melanoma and mammary tumour models

Bernard Vanhove, CEO, **Effimune**

11:00 **The CD137 Costimulatory Pathway As A Therapeutic Target**

- Discuss the rationale and underlying biology behind costimulatory receptor targeting
- Contrast CD137 with other TNF receptor antagonists
- Data will be presented from the HER2/CD137 bispecific program PRS-343 to verify the superiority of bispecific over monospecific approaches in targeting CD137

Marlon Hinner, Director, Immuno-Oncology, **Pieris**

11:30 **Development Of Differentiated Immuno-Oncology Therapeutics Using Multivalent Nanobodies**

- Overview of Ablynx's Nanobody platform technology and advantages
- Development of multi-specific Nanobody drugs for immune checkpoint modulation
- A multivalent approach for an agonistic Nanobody against the co-stimulatory immune checkpoint receptor GITR

Sandra Li, Scientist, Pharmacodynamics and Translational Medicine, **Ablynx**

12:00 **Lunch & Networking**

13:00 **Targeting The Next Generation Of Checkpoint Pathways Using A Disease-Centric Approach**

- Focussing on the underlying philosophy behind Agenus on tackling immuno oncology by the best means available
- Optimising the development of checkpoint-targeting antibodies to enhance responses
- Personalised vaccines and their efficacy for immuno-oncology

Zahra Jawad, Team Leader, Antibody Phage Display, **Agenus**

Advancing Understanding Of The Tumour Microenvironment

13:30 **Novel Inhibitors Of Tryptophan Metabolism As Cancer Immunotherapies**

- Highlight the role of the kynurenine pathway and the enzymes IDO1 and TDO in cancer immunotherapy
- Detail the discovery of novel selective and dual-acting inhibitors of IDO1 and TDO
- Discuss potential combinatorial strategies for kynurenine pathway modulators in cancer immunotherapy

Alan Wise, CEO, **IOmet Pharma**

14:00 **Analysing The Role Of Mutational Load In Response To Immune Checkpoint Blockade**

- Provide biological background by which somatic mutations can lead to the generation of private, highly immunogenic tumour antigens (neoantigens)
- Discuss association of mutational burden with response to immune-checkpoint blockade in solid tumours
- Provide outlook on clinical applications involving mutational load and neoantigens

Bastian Schilling, Researcher, Dermatology Study Centre Coordinator, **University Hospital Essen**

14:30 **Afternoon Refreshments & Networking**

15:00 **Therapeutic Modulation Of The Microenvironment In Tumour-Draining Lymph Nodes Through Local Administration Of Immune Checkpoint Inhibitors**

- Discuss how early immune suppression in the tumour-draining sentinel lymph node (SLN) relates to risk of recurrence and reduced survival
- Hear clinical evidence from trials in patients with early-stage melanoma to show that local low-dose administration of CpG-B or anti-CTLA-4 /tremelimumab can overcome tumour-induced immune suppression and boost systemic anti-tumour immunity, with long-term follow-up of CpG-B treated patients revealing significantly prolonged recurrence-free survival
- Multi-parameter profiling and *ex vivo* cultures of SLN samples provide evidence for the clinical application of (combinations of) immune checkpoint inhibitors and TLR ligands; a case in point will be presented for PD-(L)1 blockade in early-stage cervical cancer

Tanja de Gruijl, Head, Immunotherapy Lab, **Cancer Center Amsterdam**

Future Strategies For Market Success

15:30 **Panel Discussion: Future Perspectives On The Development Of Immune Checkpoint Inhibitors**

- How can past challenges be interrogated to develop successful future strategies?
- What are the most immediate challenges that need to be prioritised?
- What does the next 5-10 years hold for the field?

Tom Lillie, VP, Head of European Clinical Development, **MSD**

Udo Gaipl, Head of Radiation Immunobiology, **University Hospital Erlangen**

Nicolai Wagtmann, EVP and CSO, **Innate Pharma**

16:15 **Chair's Closing Remarks**

Tom Lillie, VP, Head of European Clinical Development, **MSD**

Workshops - Friday 18th November

Workshop A

Harnessing *In Vivo* Models For The Development Of IO Therapeutic Agents

Date: Friday 18th November **Time:** 08:00-11:00

This interactive workshop will incorporate insights into a range of *in vivo* modelling approaches, providing you with the tools to enhance preclinical development.

You'll come away with a comprehensive immuno-oncology preclinical strategy, including insights into:

- Exploring the different *in vivo* models available to develop IO therapeutics
- Syngeneic mice, GEMMs and strategies of immune system humanisation in mice
- How predictive are the humanised mouse models (predictive validity, efficacy/safety/biomarkers)?
- Use of other species for the evaluation of PK/PD, efficacy and safety
- Investigating *ex vivo* functional assays
- Exploring appropriate models to select combinations of immunotherapies

Workshop leader
Sukhvinder Sidhu
Head of Pharmacology, Oncology Drug Discovery & Preclinical Development
Sanofi

Sukhvinder obtained his PhD at the University of Manchester, Manchester, UK in 1997 and then completed his studies with postdoctoral experiences at the ICGM at Hopital Cochin in Paris, France and University of California at San Francisco, USA. At UCSF he became a junior faculty member in 2004 then eventually decided to move back to Europe where he joined Sanofi Oncology in Vitry, France initially as a lab head, in 2011 and then became Head of Pharmacology in 2013 and more recently Global Head of Pharmacology. Sukh has a wealth of experience in life science research in oncology and inflammation with a current focus on the development of in vivo and ex-vivo models for the preclinical assessment of immuno-oncology therapies.

Workshop B

Insights Into Biomarker Approaches To Enhance The Predictability Of Clinical Response

Date: Friday 18th November **Time:** 12:00-15:00

The development and utility of clinically relevant biomarkers has emerged as one of the most pressing challenges facing the immune checkpoint inhibitor field. Attend this workshop for the chance to discuss the biomarker landscape and how previous success can shape the future of biomarker development in this space.

Engage directly with a focussed group of biomarker researchers and collaborate on overcoming some of the key challenges involved in developing effective biomarkers.

Attendees will discuss:

- The utility of tumour tissue biomarkers, genetic biomarkers and host-specific biomarkers
- The true value of PD-L1 as a relevant biomarker
- Tumour-infiltrating lymphocytes as correlates of response
- Relative advantages of various biomarker assays
- Novel biomarkers across tumour types, with a focus on melanoma

Workshop leader
Rosalie Luiten
Principal Investigator, Immunodermatology Research
University of Amsterdam

Rosalie Luiten studied Biomedical Sciences and obtained her PhD in cancer immunology and immunotherapy at the University of Leiden, The Netherlands in 1998. She acquired an extensive track record in cancer immunology and dermatology by postdoctoral research at Ludwig institute for Cancer Research in Brussels, the Antoni van Leeuwenhoek Netherlands Cancer Institute (NKI-AVL) in Amsterdam and The Leiden University Medical Center. In 2005, she established her independent research group at the department of Dermatology at the Academic Medical Center (AMC) of the University of Amsterdam. Since 2008, Luiten is Head of the Laboratory of Experimental Dermatology. She was appointed as associate professor in 2012 and full professor in 2014. Rosalie Luiten is specialized in pigment cell research, in particular the relation between vitiligo and melanoma. She unravelled the autoimmune pathogenesis of vitiligo and invented a new type of melanoma immunotherapy.

Partnership Opportunities

Drug developers need technologies and service providers to help accelerate their drug development. Yet, they are telling us they currently have very low visibility on companies providing solutions that will enhance immuno-oncology development.

If your business strategy is to target the immuno-oncology space, **ICI Europe** is a critical step in realising your success. The meeting offers you **unrivalled opportunities to showcase your company, generate new business leads and source opportunities for partnerships.**

ICI Europe will bring together decision makers from pharma and biotech who are committed to speeding up the development of their ICI drugs. Whether you provide the latest **humanised tumour models, technology to discover checkpoint pathways, clinical monitoring tools** or a **combination therapy**, partnering with ICI Europe will secure your market share in this commercially booming market. Act now to stay ahead of the curve and maximise the wealth of opportunity on offer.

> "The meeting allowed us time to really engage with the attendees rather than just the few minutes we might have at a tradeshow."
>
> **Lonza**

Who Attends



ICI Event Partners

Program Partner

ABZENA
Enabling better biopharmaceuticals

Abzena offers a suite of complementary services and technologies. Its range of technologies include immunogenicity assessment, antibody drug conjugation, protein engineering, PEGylation, cell line development , GMP manufacturing and a range of bespoke assays to enables the development of better biopharmaceuticals which will have a greater chance of reaching the market.

www.abzena.com

Spotlight Partner

CAPRION

Caprion provides GLP/GCLP immune monitoring and proteomics services to 50+ major companies in the pharmaceutical and biotechnology industry for their vaccine and immunotherapy programs. Caprion's immune monitoring business unit, ImmuneCarta®, offers proprietary multiparametric flow cytometry for functional analyses of innate and adaptive immune responses. ImmuneCarta offers a complete menu of off-the-shelf and customizable assays to characterize and monitor immune response during discovery, pre-clinical, and Phase I—III clinical development.

www.caprion.com

Partner with Us

To start exploring the sponsorship opportunities which will deliver on your commercial objectives, contact:

Jason Williams
Commercial Director
Tel: +44 (0)203 141 8711
Email: Jason.williams@hansonwade.com

Venue

Maritim Hotel Munich
Goethestraße 7
80336 Munich
Germany

www.maritim.com

Overnight accommodation is not included in the registration fee.

"I thought that conference was well organized, sessions were well planned and we had a good mix of academic & pharma speakers. So overall, conference was a great success." GSK

Prices & Discounts

Package Prices	Register & Pay before 5 Aug	Register & Pay before 2 Sep	Register & Pay before 7 October	Standard Pricing
Gold: Conference & 2 workshops	€3097+ VAT **(save €600)**	€3297 + VAT **(save €400)**	€3397 + VAT **(save €300)**	€3497 + VAT **(save €200)**
Silver: Conference & 1 workshop	€2598 + VAT **(save €500)**	€2798 + VAT **(save €300)**	€2898 + VAT **(save €200)**	€2998 + VAT **(save €100)**
Bronze: Conference only	€2099+ VAT **(save €400)**	€2299 + VAT **(save €200)**	€2399 + VAT **(save €100)**	€2499 + VAT
Workshops - individual	€599 + VAT			

Team Discounts*

3+ Delegates: 10% Discount
4+ Delegates: 15% Discount
5+ Delegates: 20% Discount

*Please note: Team discounts are only valid when three or more delegates from one company book and pay at the same time. 'Early Bird' discounts require payment at the time of registration (or prior to the cut-off date) to secure the applicable discount. All advertised discounts cannot be combined with any other offer.

Registration Checklist

1. Have you checked if anyone else from your business is attending? If 3 or more of you register together, you will all benefit from reduced rates. ✔
2. Could you register your place early to take advantage of early booking rates? ✔
3. Have you carefully evaluated which package will best help you achieve your goals? ✔

When you've made your selections
Secure Your Place*

You can register your place quickly and easily online. Visit:

www.immunecheckpoint-europe.com/register

Contact us:

If you require any further information on the event, or would like us to assist you in making your booking, please contact Hanson Wade via the contact details below.

Code: 6835